European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

Novartis Canada is pleased to announce that Fabhalta® (iptacopan capsules) is now available across Canada for adult patients ...

Swiss pharmaceutical giant Novartis announced it will spend $23 billion to build and expand 10 facilities in the United ...

Swiss pharmaceutical giant Novartis announced Thursday that it plans to build a $1.1 billion research hub in San Diego as ...

Swiss pharmaceutical company, Novartis, has announced plans to build a new, $1.1 billion biomedical research complex in San ...

Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the U.S., as it grapples with renewed threats of drug import duties from the Trump ...

President Donald Trump's pressure to bring manufacturing jobs back to the U.S. appears to have influenced a pharmaceutical ...

It’s unclear whether tariffs will influence more companies to make more drugs in the U.S. like President Donald Trump is ...

It has been a choppy week for European and global markets as investors have been reacting to the frequent developments in ...

Novartis (NVS) announced a planned $23B investment over five years in U.S.-based infrastructure, ensuring all key Novartis medicines for U.S.

(Reuters) -Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 facilities in the U ...

During the upcoming Abu Dhabi Global Health Week (ADGHW), a global initiative aimed at advancing longevity science and precision medicine will be released, expected to set a new standard for ...